期刊文献+

补体系统与肿瘤的关系研究进展 被引量:8

Complement system and tumor:research progress
下载PDF
导出
摘要 补体系统是天然免疫的重要组成部分,能有效清除异物并维持内环境稳定。一直以来,补体系统的参与被认为是抑制肿瘤发生的有效手段。但近年来,越来越多的研究结果却改变了这一观点,无论是补体成分还是补体活化产物,都能分泌与肿瘤生成相关的生长因子,激活肿瘤相应的信号通路,并促进肿瘤血管生成,进而导致肿瘤的发生发展。本文就补体与肿瘤关系的研究进展进行综述。 Complement system is an important component of innate immunity and has been recognized as an effective means to inhibit tumor. However,in last decades,accumulating studies showed unexpected results that the complement components and their activation products could promote development of malignancies by secreting growth factors,activating signal pathway and promoting tumor angiogenesis. Herein,the relationship between the complement system and tumor is reviewed.
出处 《国际药学研究杂志》 CAS CSCD 2014年第5期516-521,共6页 Journal of International Pharmaceutical Research
关键词 补体 肿瘤 生长因子 信号通路 血管生成 complement tumor growth factor signal pathway angiogenesis
  • 相关文献

参考文献1

二级参考文献10

  • 1Yan Xin,Denise Jin,Stephen Eppler,Lisa A. Damico-Beyer,Amita Joshi,John D. Davis,Surinder Kaur,Ihsan Nijem,John Bothos,Amy Peterson,Premal Patel,Shuang Bai.Population Pharmacokinetic Analysis From Phase I and Phase II Studies of The Humanized Monovalent Antibody, Onartuzumab (MetMAb), in Patients With Advanced Solid Tumors[J].Journal of Clinical Pharmacology.2013(11)
  • 2Hagop Kantarjian,Deborah Thomas,Jeffrey Jorgensen,Partow Kebriaei,Elias Jabbour,Michael Rytting,Sergernne York,Farhad Ravandi,Rebecca Garris,Monica Kwari,Stefan Faderl,Jorge Cortes,Richard Champlin,Susan O’Brien.Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia[J].Cancer.2013(15)
  • 3Deborah K. Armstrong,Allen J. White,Susan C. Weil,Martin Phillips,Robert L. Coleman.Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer[J].Gynecologic Oncology.2013(3)
  • 4Michinori Ogura,Kensei Tobinai,Kiyohiko Hatake,Toshiki Uchida,Tatsuya Suzuki,Yukio Kobayashi,Masakazu Mori,Yasuhito Terui,Masahiro Yokoyama,Tomomitsu Hotta.Phase I study of obinutuzumab ( GA 101) in J apanese patients with relapsed or refractory B ‐cell non‐ H odgkin lymphoma[J].Cancer Sci.2012(1)
  • 5Anas Younes,Ajay K. Gopal,Scott E. Smith,Stephen M. Ansell,Joseph D. Rosenblatt,Kerry J. Savage,Radhakrishnan Ramchandren,Nancy L. Bartlett,Bruce D. Cheson,Sven de Vos,Andres Forero-Torres,Craig H. Moskowitz,Joseph M. Connors,Andreas Engert,Emily K. Larsen,Dana A. Kennedy,Eric L. Sievers,Robert Chen.Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin’s Lymphoma[J].Journal of Clinical Oncology.2012(18)
  • 6Barbara Pro,Ranjana Advani,Pauline Brice,Nancy L. Bartlett,Joseph D. Rosenblatt,Tim Illidge,Jeffrey Matous,Radhakrishnan Ramchandren,Michelle Fanale,Joseph M. Connors,Yin Yang,Eric L. Sievers,Dana A. Kennedy,Andrei Shustov.Brentuximab Vedotin (SGN-35) in Patients With Relapsed or Refractory Systemic Anaplastic Large-Cell Lymphoma: Results of a Phase II Study[J].Journal of Clinical Oncology.2012(18)
  • 7Sandhya Girish,Manish Gupta,Bei Wang,Dan Lu,Ian Krop,Charles Vogel,Howard Burris III,Patricia LoRusso,Joo-Hee Yi,Ola Saad,Barbara Tong,Yu-Waye Chu,Scott Holden,Amita Joshi.Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer[J].Cancer Chemotherapy and Pharmacology.2012(5)
  • 8N.N. Shah,D. Bhojwani,L.B. Silverman,J.A. Whitlock,K. Richards,M. Stetler-Stevenson,M. Buzoianu,R. Ibrahim,I. Pastan,A.S. Wayne.A Novel Anti-CD22 Immunotoxin, Moxetumomab Pasudotox (HA22, CAT-8015): Activity in Pediatric Patients with Relapsed Acute Lymphoblastic Leukemia (ALL) After Allogeneic Hematopoietic Stem Cell Transplantation (SCT)[J].Biology of Blood and Marrow Transplantation.2012(2)
  • 9Kedan Lin,Jay Tibbitts.Pharmacokinetic Considerations for Antibody Drug Conjugates[J].Pharmaceutical Research.2012(9)
  • 10MichinoriOgura,KenseiTobinai,KiyohikoHatake,ToshikiUchida,MasanobuKasai,TakashiOyama,TatsuyaSuzuki,YukioKobayashi,TakashiWatanabe,TeruhisaAzuma,MasakazuMori,YasuhitoTerui,MasahiroYokoyama,YukoMishima,ShunjiTakahashi,ChihoOno,JunkoOhata.Phase I study of inotuzumab ozogamicin (CMC‐544) in Japanese patients with follicular lymphoma pretreated with rituximab‐based therapy[J].Cancer Science.2010(8)

共引文献8

同被引文献66

引证文献8

二级引证文献30

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部